BioCentury
ARTICLE | Product Development

Creating drug master files for AAV vectors

FDA, NIH leaders want to help the business case for ultra-rare disease gene therapies. FNIH’s Bespoke Gene Therapy Consortium is the vehicle

November 29, 2021 9:26 PM GMT

Access This Article